3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
2
TP53 Y220C Mutation
1
Smoking
1
Rectal Neoplasms
1
Pulmonary Disease, Chronic Obstructive
1
Peripheral Nervous System Diseases
1
Meningioma
1
Medulloblastoma
1
Lymphoma, Mantle-Cell
1
Localized Prostate Cancer
1
Leukemia, Myeloid, Acute
1
Head and Neck Neoplasms
1
HER2 IHC3+ Advanced Colorectal Cancer
1
Genetic Diseases, Inborn
1
Deglutition Disorders
1
Cognitive Dysfunction
1
Interventions
Magnetic Resonance Spectroscopy
56
enzalutamide
44
Specimen Handling
37
apalutamide
35
Androgen Antagonists
35
Abiraterone Acetate
29
Prednisone
27
Radiosurgery
26
darolutamide
25
Docetaxel
23
Pluvicto
22
abiraterone
21
Radiotherapy
21
Leuprolide
20
Biopsy
16
relugolix
14
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
14
gallium 68 PSMA-11
12
Triptorelin Pamoate
12
Surveys and Questionnaires
12
Radiation
12
Gonadotropin-Releasing Hormone
12
X-Rays
11
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
10
cabazitaxel
9
bicalutamide
9
Standard of Care
9
Nivolumab
9
Goserelin
9
Carboplatin
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Tablets
×
90 days
×
Clear all
No trials found.